Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Innoviva Inc (INVA)

Innoviva Inc (INVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,204,944
  • Shares Outstanding, K 62,562
  • Annual Sales, $ 310,460 K
  • Annual Income, $ 179,720 K
  • EBIT $ 162 M
  • EBITDA $ 200 M
  • 60-Month Beta 0.57
  • Price/Sales 3.94
  • Price/Cash Flow 5.59
  • Price/Book 1.84

Options Overview Details

View History
  • Implied Volatility 35.67% ( -14.97%)
  • Historical Volatility 13.02%
  • IV Percentile 31%
  • IV Rank 21.58%
  • IV High 115.62% on 07/03/24
  • IV Low 13.67% on 06/10/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 7
  • Volume Avg (30-Day) 13
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 681
  • Open Int (30-Day) 705

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.98
  • Growth Rate Est. (year over year) +101,838.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.00 +1.89%
on 11/01/24
20.37 -4.96%
on 10/17/24
-0.31 (-1.58%)
since 10/04/24
3-Month
17.98 +7.68%
on 08/06/24
20.37 -4.96%
on 10/17/24
+0.28 (+1.47%)
since 08/02/24
52-Week
13.31 +45.45%
on 11/10/23
20.37 -4.96%
on 10/17/24
+5.73 (+42.04%)
since 11/03/23

Most Recent Stories

More News
Innoviva: Q2 Earnings Snapshot

Innoviva: Q2 Earnings Snapshot

INVA : 19.37 (+0.57%)
Innoviva: Q1 Earnings Snapshot

Innoviva: Q1 Earnings Snapshot

INVA : 19.37 (+0.57%)
Innoviva: Q4 Earnings Snapshot

Innoviva: Q4 Earnings Snapshot

INVA : 19.37 (+0.57%)
Chart of the Day: Innoviva - Individual Investor Favorite

The Chart of the Day belongs to the biopharma company Innoviva (INVA) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest...

INVA : 19.37 (+0.57%)
Innoviva: Q3 Earnings Snapshot

Innoviva: Q3 Earnings Snapshot

INVA : 19.37 (+0.57%)
Innoviva: Q2 Earnings Snapshot

Innoviva: Q2 Earnings Snapshot

INVA : 19.37 (+0.57%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

INVA : 19.37 (+0.57%)
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific...

INVA : 19.37 (+0.57%)
Innoviva: Q1 Earnings Snapshot

Innoviva: Q1 Earnings Snapshot

INVA : 19.37 (+0.57%)
Innoviva Announces Retirement of Board Chairman

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the “Board”) today announced that Mr. Bickerstaff...

INVA : 19.37 (+0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance,...

See More

Key Turning Points

3rd Resistance Point 20.47
2nd Resistance Point 20.13
1st Resistance Point 19.69
Last Price 19.37
1st Support Level 18.91
2nd Support Level 18.57
3rd Support Level 18.13

See More

52-Week High 20.37
Last Price 19.37
Fibonacci 61.8% 17.67
Fibonacci 50% 16.84
Fibonacci 38.2% 16.01
52-Week Low 13.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar